成纤维细胞激活蛋白抑制剂引导的分子影像与治疗的观察者间一致性
研究纳入49例肿瘤患者的68Ga-FAPI-4 PET/CT,由4名盲法阅片者独立判读,评估视觉与定量分析的观察者间一致性及是否考虑FAPI引导的内照射治疗。总体扫描印象一致性为一般(ICC 0.42),淋巴结转移数目、受累器官数目及器官转移数目一致性良好(ICC≥0.63),决定是否行内照射治疗的一致性为一般(ICC 0.59)。
要点
- 总体扫描印象的观察者间一致性为一般(ICC 0.42;95%CI 0.27-0.57)。
- 淋巴结转移数目、受累器官数目、器官转移数目一致性良好(ICC≥0.63)。
- 决定是否考虑FAPI引导内照射治疗的一致性为一般(ICC 0.59;95%CI 0.46-0.73)。
核心结论
- FAPI引导的分子影像与治疗获得一般至良好的观察者间一致性,支持该放射性示踪剂用于临床常规和多中心试验。
研究设计与样本
- 对49例肿瘤患者的68Ga-FAPI-4 PET/CT以随机顺序由4名盲法阅片者独立判读,评估观察者间一致性。
主要发现
- 视觉评估中,总体扫描印象一致性为一般(ICC 0.42;95%CI 0.27-0.57)。
- 受累淋巴结区域数目一致性为一般(ICC 0.59;95%CI 0.45-0.72),淋巴结转移数目、受累器官数目和器官转移数目一致性良好(ICC≥0.63)。
- 定量分析中,淋巴结病灶一致性良好(ICC 0.70;95%CI 0.48-0.88),器官病灶一致性仅为一般(ICC 0.43;95%CI 0.26-0.60)。
- 背景组织中,未受累肝实质一致性良好(ICC 0.68;95%CI 0.54-0.79),血池一致性为一般(ICC 0.43;95%CI 0.29-0.58)。
- 决定是否考虑FAPI引导内照射治疗时,一致性为一般(ICC 0.59;95%CI 0.46-0.73)。
关键数值与推荐
- 观察者间一致性采用组内相关系数(ICC)评估,按Cicchetti标准判读:0.4-0.59为一般,0.6-0.74为良好。
- 视觉评估包括总体扫描印象、器官/淋巴结转移数目及受累器官/淋巴结区域数目。
- 每个器官隔室最多识别3个靶病灶(定义为最大和/或摄取最强者),用于淋巴结和器官病灶的定量一致性评估。
- 定量分析还包括未受累肝实质和血池作为潜在参考组织。
- 阅片者需根据摄取强度和病变广泛程度判断是否应考虑FAPI引导内照射治疗。
临床怎么用
- 原文结论认为该一致性结果支持将FAPI示踪剂用于临床常规和多中心试验。
- 原文未据此给出具体的临床操作推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Fibroblast activation protein (FAP) has emerged as a novel target for FAP inhibitor (FAPI)-directed molecular imaging and endoradiotherapy (ERT). We aimed to assess the interobserver agreement rates for interpretation of 68Ga-FAPI-4 PET/CT and decision for ERT. PATIENTS AND METHODS: A random order of 68Ga-FAPI-4 PET/CTs from 49 oncology patients were independently interpreted by 4 blinded readers. Per scan, visual assessment was performed, including overall scan impression, number of organ/lymph node (LN) metastases, and number of affected organs/LN regions. Moreover, a maximum of 3 target lesions, defined as largest in size and/or most intense, per organ compartment were identified, which allowed for an additional quantitative interobserver assessment of LN and organ lesions. To investigate potential reference tissues, quantification also included unaffected liver parenchyma and blood pool. Readers also had to indicate whether FAPI-directed ERT should be considered (based on intensity of uptake and widespread disease). Interobserver agreement rates were evaluated using intraclass correlation coefficients (ICCs) and interpreted according to Cicchetti (with 0.4-0.59 indicating fair, and 0.6-0.74 good, agreement). RESULTS: On a visual basis, the agreement rate for an overall scan impression was fair (ICC, 0.42; 95% confidence interval [CI], 0.27-0.57). The concordance rate for number of affected LN areas was also fair (ICC, 0.59; 95% CI, 0.45-0.72), whereas the number of LN metastases, number of affected organs, and number of organ metastases achieved good agreement rates (ICC, ≥0.63). In a quantitative analysis, concordance rates for LN were good (ICC, 0.70; 0.48-0.88), but only fair for organ lesions (ICC, 0.43; 0.26-0.60). In regards to background tissues, ICCs were good for unaffected liver parenchyma (0.68; 0.54-0.79) and fair for blood pool (0.43; 0.29-0.58). When readers should decide on ERT, concordance rates were also fair (ICC, 0.59; 95% CI, 0.46-0.73). CONCLUSIONS: For FAPI-directed molecular imaging and therapy, a fair to good interobserver agreement rate was achieved, supporting the adoption of this radiotracer for clinical routine and multicenter trials.
引用
- Serfling SE, Hartrampf PE, Zhi Y, et al. Interobserver Agreement Rates on Fibroblast Activation Protein Inhibitor-Directed Molecular Imaging and Therapy. Clin Nucl Med. 2022. PMID: 35439187. doi:10.1097/RLU.0000000000004189
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。